EUVIMEDEUVIMED entdecken
Crossref

Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D

Shuang Li, Jingfei Liu, Chun Yang, Yanjun Jin, Yiwen Zhou, Hang Zhao, Zhangyao Su, Yu Fu, Mei Zhang iD, XianYong Yin, Tao Yang iD, Yong Gu iD und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Shuang Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Endocrinology and Metabolism, Jiangsu Province Hospital, First Affiliated Hospital with Nanjing Medical University, Nanjing 210029,…. Hauptthemen laut MEDLINE: Glucagon, Diabetes Mellitus, Type 2, Blood Glucose, Liver. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology, National Natural Science Foundation of China, Jiangsu Provincial Medical Key Discipline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Metabolic dysfunction–associated steatotic liver disease is prevalent in type 2 diabetes (T2D) and exacerbates hyperglycemia, but its impact on postprandial glucagon suppression remains unclear.

Objective

To investigate the association between hepatic steatosis and impaired glucagon suppression during oral glucose tolerance tests (OGTTs), and to evaluate the mediating role of glucagon dysregulation in linking liver fat to glycemic control.

Methods

In this cross-sectional study, 604 patients with T2D underwent liver fat quantification via the FibroScan Pro controlled attenuation parameter (CAP) and liver ultrasound. Postprandial glucagon suppression was assessed during 180-minute OGTTs (0, 30, 60, 120, 180 minutes), with continuous glucose monitoring (CGM) in 287 participants. Glucagon suppression was calculated for early (0-30 minutes), late (30-180 minutes), and overall (0-180 minutes) phases. Multivariable regression and mediation analyses tested associations between CAP, glucagon dynamics, and CGM-derived glycemic profiles.

Results

Patients with T2D with MASLD (CAP ≥238 dB/m, n = 414) exhibited significantly impaired glucagon suppression compared to non-MASLD controls (n = 190) across all phases (all P < .05). Each 1-SD CAP increase independently predicted attenuated dose-dependent suppression in all phases (standardized β = 0.183–0.303, P < .001). Males showed greater suppression impairment than females and stronger CAP-associated dysregulation. Mediation analysis revealed that glucagon suppression mediated 14.9% to 33.9% of the adverse effects of liver fat on hyperglycemia.

Conclusion

Liver fat accumulation in T2D is strongly associated with defective postprandial glucagon suppression, particularly in males, which mediates nearly one-third of its detrimental impact on glycemic control. Targeting hepatic steatosis and glucagon signaling may offer novel therapeutic strategies for T2D management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucagonDiabetes Mellitus, Type 2Blood GlucoseLiverFatty LiverHumansMaleFemaleCross-Sectional StudiesMiddle AgedPostprandial PeriodAgedGlucose Tolerance TestGlycemic ControlAdult

Stichwörter der Autor:innen

continuous glucose monitoringglucagon suppressionliver–α axismetabolic dysfunction–associated steatotic liver diseasetype 2 diabetes

Substanzen

GlucagonBlood Glucose

Autor:innen und Institutionen

  • The Department of Endocrinology and Metabolism, Jiangsu Province Hospital, First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
  • Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu, China.

ORCID-Profile: Mei Zhang, Tao Yang, Yong Gu, Yang Chen

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology
  • National Natural Science Foundation of China
  • Jiangsu Provincial Medical Key Discipline

Zitieren

APA

Li, S., Liu, J., Yang, C., Jin, Y., Zhou, Y., Zhao, H., Su, Z., Fu, Y., Zhang, M., Yin, X., Yang, T., Gu, Y., & Chen, Y. (2025). Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf303

Vancouver

Li S, Liu J, Yang C, Jin Y, Zhou Y, Zhao H, et al. Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf303

BibTeX
@article{Li2025,
  author = {Li, Shuang and Liu, Jingfei and Yang, Chun and Jin, Yanjun and Zhou, Yiwen and Zhao, Hang and Su, Zhangyao and Fu, Yu and Zhang, Mei and Yin, XianYong and Yang, Tao and Gu, Yong and Chen, Yang},
  title = {Impaired Glucagon Suppression Accompanied by Liver Fat Accumulation Mediated Worse Blood Glucose Control in Patients With T2D},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf303}
}
Kostenlos starten →